Niklas Mattsson-Carlgren, MD, PhD; Lyduine E. Collij, PhD; Erik Stomrud, MD, PhD; et al.
JAMA Neurol. Published online December 4, 2023. doi:10.1001/jamaneurol.2023.4596
This cohort study analyzes data from participants with cognitive concerns to determine whether plasma biomarkers can identify amyloid β–positive individuals who do not yet have a high tau burden in the brain and would be suitable candidates for treatment with antiamyloid immunotherapies in Alzheimer disease.
Shijun Yan, MSc; Cheng Jiang, PhD; Annette Janzen, MD; et al.
open access
JAMA Neurol. Published online December 4, 2023. doi:10.1001/jamaneurol.2023.4398
This study investigate whether α-synuclein in neuronally derived serum-extracellular vesicles identifies individuals at risk of developing Parkinson disease and related dementia.